SAB Biotherapeutics Warrant
SABSW
14 hedge funds and large institutions have $863K invested in SAB Biotherapeutics Warrant in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 0 closing their positions.
8% more funds holding
Funds holding: 13 → 14 (+1)
66% less capital invested
Capital invested by funds: $2.55M → $863K (-$1.69M)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$4.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$710 |
| 2 |
Morgan Stanley
New York
|
-$435 |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$228 |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$177 |
| 5 |
Jane Street
New York
|
-$171 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $520K | +$4.8K | +21,067 | +6% |
|
|
SCM
2
Shaolin Capital Management
Miami,
Florida
| $156K | -$228 | -1,000 | -0.1% |
|
|
RCM
3
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| $81K | – | – | – |
|
4
Balyasny Asset Management
Chicago,
Illinois
| $42K | – | – | – |
|
|
5
Morgan Stanley
New York
| $22K | -$435 | -1,907 | -1% |
|
|
YCM
6
Yakira Capital Management
Westport,
Connecticut
| $17K | – | – | – |
|
|
EPM
7
Equitec Proprietary Markets
Chicago,
Illinois
| $7K | – | – | – |
|
|
HF
8
HRT Financial
New York
| $6K | -$710 | -3,116 | -7% |
|
|
9
Citadel Advisors
Miami,
Florida
| $3K | -$177 | -776 | -4% |
|
10
Walleye Capital
New York
| $3K | – | – | – |
|
|
11
Jane Street
New York
| $2K | -$171 | -750 | -7% |
|
12
Walleye Trading
New York
| $2K | – | – | – |
|
|
13
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | +$2.49K | +10,944 | New |
|
SABSW Hedge Fund Activity: Q2 2022 in Review
14 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q2 2022, worth a combined $863K — down 66% from $2.55M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SABSW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 5 trimmed.
The largest buyer was LMR Partners, adding an estimated $4.8K. The largest seller was HRT Financial, cutting an estimated $710.
- 14 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q2 2022, up from 13 in Q1 2022.
- Funds reported $863K of SAB Biotherapeutics Warrant stock for Q2 2022, down 66% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q2 2022 and 0 closed out, a net change of +1 holder.
- The largest SAB Biotherapeutics Warrant buyer in Q2 2022 was LMR Partners, an estimated $4.8K added.
- The largest SAB Biotherapeutics Warrant seller in Q2 2022 was HRT Financial, an estimated $710 sold.
Based on aggregated 13F filings for Q2 2022.